Amprenavir
Severe
Database
Drug interaction classified as: excretion
Source: DDInter
Drug reference
berotralstat
Plasma kallikrein inhibitor (HAE prophylaxis) · Hereditary Angioedema
START
150 mg PO once daily with food
TYPICAL MAX
150 mg/day (no added benefit, more QT risk above)
STOP IF
Significant QT prolongation or hepatotoxicity
WATCH
LFTs, ECG if QT-drug co-use; not for acute attacks
CDSCO approvedATC B06AC06
KDIGO 2024 + manufacturer label
- ONSET
- 2h · absorption
- PEAK
- 5h · Tmax
- t½
- 3.9d · t½
- DURATION
- 1d · once-daily
EXCRETION
Mainly faecal; minor renal
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Limited data; use only if clearly needed.
FDA category + note
Top interactionssee all 12 →
- AmprenavirSevereDatabaseDDInter
- AvanafilSevereDatabaseDDInter
- AzithromycinSevereDatabaseDDInter
- BosutinibSevereDatabaseDDInter
Mechanism
Oral, selective inhibitor of plasma kallikrein, reducing bradykinin generation and thereby preventing hereditary angioedema attacks.
Indications
Routine prophylaxis to prevent hereditary angioedema (HAE) attacks (≥12 years)
Dosing
- Adult
- 150 mg PO once daily with food.
- Pediatric
- ≥12 y: 150 mg once daily (same as adult).
- Renal adjustment
- No adjustment for mild–moderate; not studied/avoid in severe (eGFR <30 / ESRD).
- Hepatic adjustment
- Moderate–severe impairment: not recommended (limited data).
- Geriatric
- No specific adjustment.
- Max dose
- 150 mg/day (no benefit and more QT risk at higher doses)
Pharmacokinetics
Onset
Attack-rate reduction over weeks of prophylaxis
Peak effect
~5 h (Tmax)
Duration
~24 h (once-daily)
Half-life
~93 h
Bioavailability
Low-moderate; taken with food
Protein binding
~99%
Metabolism
Hepatic CYP2D6/CYP3A4; P-gp substrate/inhibitor
Excretion
Mainly faecal; minor renal
Contraindications
- Hypersensitivity
- Caution: QT prolongation at supratherapeutic doses; hepatic impairment
Side effects
Common
Abdominal painDiarrhoeaNausea/vomitingHeadacheBack painGERD
Serious
- QT prolongation (supratherapeutic/with QT drugs)
- Hypersensitivity
- Transaminase elevation
Pregnancy & lactation
Pregnancy
Limited data; use only if clearly needed.
Lactation
Limited data; weigh benefit/risk.
Drug interactions
Avanafil
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Azithromycin
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Bosutinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Brexpiprazole
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Cabozantinib
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Capmatinib
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: excretion
Source: DDInter
Carvedilol
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Cefiderocol
Severe
Database
Drug interaction classified as: excretion
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Cilostazol
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Related guidelines
Infective endocarditis prevention
NICE · Cardiology / Dentistry · 2008
Infective endocarditis prevention
AHA · Cardiology / Dentistry · 2007
Infective endocarditis prevention
ADA_DENTAL · Dentistry · 2015
Prevention of mother-to-child HIV transmission
NACO · Infectious Disease · 2023
Stroke and TIA — secondary prevention
AHA · Neurology · 2021
Ask House about berotralstat
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20